Isobutyryl-CoA dehydrogenase deficiency associated with autism in a girl without an alternative genetic diagnosis by trio whole exome sequencing: A case report by Eleftheriadou, M. (Maria) et al.
Mol Genet Genomic Med. 2021;00:e1595.    | 1 of 10
https://doi.org/10.1002/mgg3.1595
wileyonlinelibrary.com/journal/mgg3
Received: 3 September 2020 | Revised: 18 December 2020 | Accepted: 21 December 2020
DOI: 10.1002/mgg3.1595  
C L I N I C A L  R E P O R T
Isobutyryl-CoA dehydrogenase deficiency associated with autism 
in a girl without an alternative genetic diagnosis by trio whole 
exome sequencing: A case report
Maria Eleftheriadou1 |   Evita Medici- van den Herik2 |   Kyra Stuurman1 |    
Yolande van Bever1 |   Debby M. E. I. Hellebrekers3 |   Marjon van Slegtenhorst1 |   
George Ruijter1 |   Tahsin Stefan Barakat1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
1Department of Clinical Genetics, 
Erasmus MC University Medical Center, 
Rotterdam, the Netherlands
2Department of Neurology, Erasmus MC 
University Medical Center, Rotterdam, 
the Netherlands
3Department of Clinical Genetics, 
Maastricht University Medical Center, 
Maastricht, the Netherlands
Correspondence
Tahsin Stefan Barakat, Department 
of Clinical Genetics, Erasmus MC 




ZonMw, Grant/Award Number:  
Veni grant 91617021
Abstract
Background: Isobutyryl-CoA dehydrogenase (IBD) is a mitochondrial enzyme cata-
lysing the third step in the degradation of the essential branched-chain amino acid 
valine and is encoded by ACAD8. ACAD8 mutations lead to isobutyryl-CoA dehydro-
genase deficiency (IBDD), which is identified by increased C4-acylcarnitine levels. 
Affected individuals are either asymptomatic or display a variety of symptoms during 
infancy, including speech delay, cognitive impairment, failure to thrive, hypotonia, 
and emesis.
Methods: Here, we review all previously published IBDD patients and describe a girl 
diagnosed with IBDD who was presenting with autism as the main disease feature.
Results: To assess whether a phenotype-genotype correlation exists that could explain 
the development or absence of clinical symptoms in IBDD, we compared CADD 
scores, in silico mutation predictions, LoF tolerance scores and C4-acylcarnitine lev-
els between symptomatic and asymptomatic individuals. Statistical analysis of these 
parameters did not establish significant differences amongst both groups.
Conclusion: As in our proband, trio whole exome sequencing did not establish an 
alternative secondary genetic diagnosis for autism, and reported long-term follow-up 
of IBDD patients is limited, it is possible that autism spectrum disorders could be one 
of the disease-associated features. Further long-term follow-up is suggested in order 
to delineate the full clinical spectrum associated with IBDD.
K E Y W O R D S
autism, genotype-phenotype correlation, isobutyryl-CoA dehydrogenase deficiency, whole exome 
sequencing
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1 |  INTRODUCTION
Isobutyryl-CoA dehydrogenase (IBD), encoded by the 
ACAD8 gene (OMIM #604773) on chromosome 11q25, 
belongs to the Acyl-CoA dehydrogenase (ACADs) family 
which is a group of mitochondrial enzymes involved in the 
catabolism of fatty acids and branched-chain amino acids 
(Ikeda et al., 1983). It is responsible for the conversion of 
isobutyryl-CoA to methylacrylyl-CoA at the third step in the 
catabolism of the essential branched-chain amino acid valine 
(Andresen et al., 2000). Isobutyryl-CoA dehydrogenase defi-
ciency (OMIM #611283, IBDD) (Roe et al., 1998) is a rare 
autosomal recessive disorder that is caused by bi-allelic muta-
tions in ACAD8, which reduce or eliminate the ability of IBD 
to catabolize valine (Andresen et al., 2000). IBDD causes 
blockage of valine oxidation resulting in the accumulation 
of isobutyryryl-CoA, followed by transesterification with 
carnitine which leads to the formation of C4-acylcarnitine 
and free CoA and excretion of acylcarnitines in urine (Reuter 
& Evans, 2012). In some cases, carnitine re-uptake by the 
carnitine transporter in renal cells is inhibited, resulting in 
systemic secondary depletion of carnitine (Reuter & Evans, 
2012). Therefore, IBDD patients present with accumulation 
of C4-acylcarnitine in plasma and urine and in some cases 
secondary carnitine deficiency.
IBDD, in most cases, is suspected after initial aberrant 
newborn screening (NBS) performed by tandem mass spec-
trometry (MS/MS) to determine C4-acylcarnitine levels 
which may represent isobutyrylcarnitine or butyrylcarnitine. 
However, elevated levels of C4-acylcarnitine are not IBDD 
specific and are also observed in short-chain acyl-CoA de-
hydrogenase deficiency and ethylmalonic encephalopathy 
(Zafeiriou et al., 2007). In vitro probe studies of fibroblast 
fatty acid oxidation and specific detection of isobutyrylgly-
cine in urine can help to distinguish between these disorders. 
However, final diagnosis of IBDD requires isobutyryl-CoA 
dehydrogenase activity determination or genetic testing for 
mutations in ACAD8 (Koeberl et al., 2003). Affected indi-
viduals are reported to be either asymptomatic or develop 
symptoms during infancy or childhood, such as mild intel-
lectual disability, speech delay, and failure to thrive with em-
esis (Koeberl et al., 2003; Lin et al., 2018; Oglesbee et al., 
2007; Pedersen et al., 2006; Roe et al., 1998; Santra et al., 
2017; Sass et al., 2004). Since, most cases of IBDD reported 
in literature have been identified through expanded NBS and 
limited data on their clinical follow-up is available, at present 
the complete clinical spectrum of this disorder is undefined. 
Here, we review all previously described IBDD cases and 
report a girl presenting with autism, diagnosed with IBDD 
upon metabolic and targeted genetic investigation, in which 
subsequent trio whole exome sequencing (WES) did not es-
tablish an alternative genetic diagnosis that could explain 
autism.
2 |  METHODS
2.1 | Ethical compliance
Parents gave written informed consent for publication of 
anonymized medical data and clinical photographs of the 
proband, collected in a clinical care setting. All metabolic 
investigations were performed in a clinical diagnostic set-
ting. Use of genome-wide genetic investigations, including 
trio WES in a clinical setting, was approved by the Erasmus 
MC Institutional Review Board (METC-2012-387).
2.2 | Trio whole exome sequencing
Trio WES was performed and analysed as previously de-
scribed (Hengel et al., 2020; Perenthaler et al., 2020). In short, 
genomic DNA was isolated from peripheral blood leukocytes 
of the proband and both parents and exome-coding DNA was 
captured with the Agilent SureSelect Clinical Research Exome 
(CRE) kit (v2). Sequencing was performed on an Illumina 
HiSeq 4000 with 150 bp paired end reads. Reads were aligned 
to hg19 using BWA (BWA-MEM v0.7.13) and variants 
were called using the GATK haplotype caller (v3.7 (refer-
ence: http://www.broad insti tute.org/gatk/). Detected variants 
were annotated, filtered and prioritized using the Bench lab 
NGS v5.0.2 platform (Agilent technologies). Initially, only 
genes known to be involved in intellectual disability were 
analyzed, followed by a full exome analysis. The encoun-
tered ACAD8 variant (reference transcript NM_014384.2) 
was verified by Sanger sequencing using the following 




2.3 | Biochemical analysis
Acylcarnitine concentrations in plasma and urine were meas-
ured by flow-injection tandem mass spectrometry (Vreken 
et al., 1999). Routine screening of urine organic acids was 
performed by gas chromatography-mass spectrometry of me-
thyl derivatives.
2.4 | Literature search
Literature on IBDD was searched in PubMed (last assessed: 
13 June 2020), focusing on publications in English. This re-
sulted in 41 publications, of which 17 were dealing with pa-
tients affected with IBDD and were, therefore, included in 
our review.
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2.5 | In silico analysis and  
genotype-phenotype correlation
Combined Annotation Dependent Depletion (CADD) scores 
(v1.4) (Kircher et al., 2014), representing the deleteriousness 
of single nucleotide variants and insertion/deletions variants 
in the human genome, were retrieved for each variant found 
in IBDD patients from https://cadd.gs.washi ngton.edu/. 
MutationTaster (Schwarz et al., 2014) was used with de-
fault settings (http://www.mutat ionta ster.org/). To determine 
LoF tolerance and display encountered variants in ACAD8, 
MetaDome (Wiel et al., 2019) (https://stuart.radbo udumc.nl/
metad ome/), was used, as we described before (Nabais Sá 
et al., 2020). To determine whether mutation characteristics 
were different between asymptomatic and symptomatic in-
dividuals, the average CADD and LoF score for both groups 
was calculated (summing up values from both alleles per 
individual) and the 95% confidence interval was calculated 
to assess whether differences were significant (p <  .05). To 
assess a possible correlation between C4-acylcarnitine levels 
detected by MS/MS blood spot in NBS and the development 
of clinical symptoms in IBDD patients, the average C4-
acylcarnitine levels were compared between symptomatic 
versus asymptomatic group and the differences assessed 
using the same statistics.
3 |  RESULTS
3.1 | Case report
The proband is a currently 11-year-old girl (Figure 1a), 
born by vacuum extraction at 40  weeks of gestation as 
the first child to distantly related Turkish, healthy parents. 
Pregnancy was uneventful, and birth weight was 3585 gram 
(p50). The start was normal, and no congenital anomalies 
or major dysmorphic features were noticed. A 4-year-old 
younger brother is healthy and has no medical issues, with 
no other cases of autism known in the family. The first year 
of the girl was uneventful. Motor development was nor-
mal, with independent ambulation at the age of 12 months. 
Parents noticed lack of interaction and lack of social eye 
contact early on. At the age of 2 years and 5 months, she 
first came to medical attention due a severe lack of speech 
development, which was assumed to be caused by hearing 
problems. At that age, she only expressed a few, barely 
understandable words and made some sounds. However, 
Extensive ENT investigations were normal, after which, at 
the age of 2 years and 7 months, a multidisciplinary neu-
ropsychological assessment was performed showing inter-
nalizing behavior and a lack of social interactions. Further 
child psychiatry assessment lead to the diagnosis of autism 
at the age of 3 years (DSM-IV classification: axis I:299.00; 
axis II: 799.90, axis III: no somatic disorder; axis IV: bi-
lingual education; axis V:cGas:35). Pivotal Response 
Treatment led to some improvements in social communi-
cation, allowing her to follow pre-school medical day care 
and improving in play interactions with other children. 
Toilet training was achieved at the age of 5 years. At the age 
of 5 years and 4 months, she was referred to the neurology 
department for assessment of a cause of her autism. At that 
age, she was described as a quiet child, being in her own 
world, and speaking few words. Motor development was 
normal, and no focal neurological abnormalities were seen. 
An EEG was normal. A brain MRI at the age of 5 years and 
10 months showed a structurally normal brain (Figure 1b), 
with no signs of aberrant neuronal migration or metabolic 
disorders, and no signs of previous asphyxia. Routine blood 
investigations and FGF-21 in serum were normal. SNP-array 
analysis revealed several runs of homozygosity (ROH, in 
total 42 Mb) in line with the distant consanguinity between 
parents, and a not-previously reported variant of unknown 
significance (loss of approximately 533 kb in band 7p15.3, 
arr 7p15.3(22,126,627-22,659,465) x1 (hg18)), which was 
inherited from the unaffected father. Metabolic testing 
showed increased C4-carnitine in plasma and urine, in-
creased isobutyrylglycine and decreased C4-carnitine/isobu-
tyryl-carnitine ratios, all suggestive of IBDD (Figure 1e). 
Subsequent next generation sequencing based gene panel 
analysis of genes implicated in metabolic diseases found a 
homozygous variant in ACAD8 (NM_014384.2 (ACAD8): 
c.289G> A, p.Gly97Arg) (Figure 1c,d). This variant is 
found nine times heterozygous but not homozygous in 
GnomAD (MAF 0.0000358), is predicted to be disease 
causing by MutationTaster (Schwarz et al., 2010), has a 
CADD score (v1.4) of 31 (Kircher et al., 2014) and has pre-
viously been identified in three affected individuals with 
IBDD (Oglesbee et al., 2007; Santra et al., 2017; Yun et al., 
2015), thereby confirming the diagnosis of IBDD in our 
proband. Subsequent suppletion with carnitine (2x daily, 
500  mg) lead to a subjective increase in appetite but did 
not improve the autism phenotype. Cardiologic evaluation, 
including ECG and cardiac ultrasound did not show any 
abnormalities. Investigation at the Clinical Genetics outpa-
tient clinic at the age of 8 years and 7 months showed stable 
normal growth (with head circumference, height and weight 
all between 0 and −1 SD at multiple measurements over the 
years), and no major dysmorphic features other than a mild 
2–3 toe syndactyly. She was following special education, 
and speech was limited to a few words and noises. Given the 
severity of autism, a possible second genetic disorder was 
considered. Therefore, trio WES was performed in a clini-
cal setting, which passed all clinical grade quality controls 
for sequencing coverage. Analysis first focused on a panel 
of ~1,200 genes involved in intellectual disability, followed 
by a complete open exome analysis. A variant of unknown 
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significance in DNA2 (OMIM 601810, NM_001080449.2 
(DNA2) c.2036-2037 ins AA, p. (His679Glnfs*10)) in-
herited from the unaffected mother was found, but besides 
the previously identified homozygous ACAD8 variant no 
other likely disease implicated variant was identified. Both 
parents were heterozygous carriers of the ACAD8 vari-
ant. The unaffected brother was not available for genetic 
investigations.
F I G U R E  1  (a) Facial image of IBDD proband. (b) Midsagital T1 and axial T2 weighted brain MRI of the IBDD proband, showing normal 
structural brain morphology. (c) Family pedigree showing segregation of the ACAD8 variant; N/A, not available for genetic testing.  
(d) Chromatogram showing the ACAD8 c.289G> A, p.Gly97Arg variant (NM_014384.2) in a homozygous state in the proband and in a 
heterozygous state in both parents. (e) Overview of metabolic investigations. aButyryl-carnitine + isobutyryl-carnitine bEthylmalonic acid is normal 
in IBDD, but elevated in SCAD or ETHE1 deficiency. (f) Mutational spectrum of ACAD8 from all described IBDD patients. ACAD8 consists 
of 11 coding exons (blue). Variants identified in symptomatic patients are marked (*), red boxed variants are found in a homozygous state in 
symptomatic individuals. LoF tolerance landscape from MetaDome analysis is indicated
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3.2 | Review of the literature
Including our patient, to date, 47 individuals with IBDD, with 
a broad variety of ethnic backgrounds, have been described 
(Battaile et al., 2004; Koeberl et al., 2003; Lin et al., 2018; 
Nguyen et al., 2002; Oglesbee et al., 2007; Pedersen et al., 
2006; Pena et al., 2012; Roe et al., 1998; Sadat et al., 2020; 
Santra et al., 2017; Sass et al., 2004; Scolamiero et al., 2015; 
T. Wang et al., 2019; W. Wang et al., 2019; Yoo et al., 2007; 
Yun et al., 2015) of which 22 are female, 17 are male and for 
eight cases gender was not reported (Table 1). Metabolic data 
have been described for 45 individuals, of which 38 have ge-
netically confirmed bi-allelic variants in ACAD8. Of these 38 
genetically confirmed individuals, 12 showed clinical symp-
toms, 24 are reported to be asymptomatic, and for two indi-
vidual no clinical data have been described.
Clinical symptoms reported include neurodevelopmental 
delay/intellectual disability (2/36), hypotonia (3/36), speech 
delay (4/36), learning disability (2/36), emesis (4/36), failure 
to thrive (3/36), congenital heart malformation (2/36), dilated 
cardiomyopathy (1/36) and others (8/36) (Table 1). The aver-
age age at last follow-up was 4.2 years (SD = 3.1 years), and 
for at least 10 patients, no follow-up after the age of 3 years 
has been reported.
To assess whether a genotype-phenotype correlation 
exists, we first mapped all reported pathogenic variants in 
ACAD8 (Figure 1f). Variants are widely distributed along the 
gene, including mutations in the N- and C-terminal alpha- 
helical domain and the medial beta-strand domain, with no 
clear differences in spatial localisation between symptomatic 
and asymptomatic individuals. The average CADD score was 
27.2, 95%CI [24.2, 30.2], in the symptomatic group com-
pared to 26.7, 95%CI [24.6, 28.7], in the asymptomatic group 
which was slightly but not significantly lower. Similarly, we 
did not find a difference in the average LoF tolerance score 
between the two groups (0.63, 95%Cl [0.56, 0.7] and 0.679, 
95%CI [0.59, 0.77] in symptomatic and asymptomatic re-
spectively). We next assessed whether a correlation exists 
between the levels of C4-acylcarnitine and clinical symp-
toms. The average C4-acylcarnitine levels detected by MS/
MS blood spot analysis was 2.124  μmol/L, 95%CI [1.56, 
2.59], in the symptomatic group compared to 1.996, 95%CI 
[1.74, 2.25] in the asymptomatic group. Therefore, no clear 
genotype-phenotype or biochemical correlation explains 
phenotypical differences between IBDD patients.
4 |  DISCUSSION
Here, we report an individual diagnosed with IBDD and 
autism, and review all previously described IBDD cases. 
Whereas the majority of IBDD cases has been reported to 
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manifesting clinical phenotypes, including neurodevelop-
mental and speech delay. No clear genotype-phenotype 
correlation emerged from our analysis, and no association 
between C4-acylcarnitine levels in NBS and clinical features 
was identified. Most IBDD individuals were identified dur-
ing NBS, and reported clinical information and long-term 
follow-up is limited. Hence, at present, the clinical spectrum 
of this disorder remains to be elucidated. Although autism 
has not yet been specifically reported to be associated with 
IBDD, at least three and one previously reported individuals 
displayed speech delay or neurodevelopmental delay, respec-
tively (Koeberl et al., 2003; Lin et al., 2018; Pedersen et al., 
2006; Sass et al., 2004), and many other individuals were 
reported at an early age at which a autism diagnosis might not 
yet have been possible to establish (Johnson et al., 2007). As 
in the reported symptomatic cases no further genetic analysis 
has been performed after the IBDD diagnosis, it remains pos-
sible that in a number of cases a secondary genetic diagnosis 
could explain some of the clinical phenotypes. However, in 
our case, extensive genetic investigations including SNP-
array and trio WES, aiming to identify a confounding sec-
ondary genetic cause, did not establish an alternative genetic 
diagnosis. Although we cannot exclude that with the current 
clinical technology, an alternative genetic diagnosis was 
missed, for example due to a genetic variant in non-coding 
regions that are not assessed during WES (Perenthaler et al., 
2019), it seems as likely that there is no secondary genetic 
cause explaining the presence of autism in this individual. 
Hence, it is possible that autism spectrum features might be 
associated with IBDD, similar to the occurrence of autism in 
many other inborn errors of metabolism including those in 
related pathways (Novarino et al., 2012; Simons et al., 2017). 
Future long-term follow-up of IBDD cases will be necessary 
to further delineate the clinical phenotype of this metabolic 
disorder.
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